|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Zhang S, Fu Y, Wang D and Wang J: Icotinib
enhances lung cancer cell radiosensitivity in vitro and in vivo by
inhibiting MAPK/ERK and AKT activation. Clin Exp Pharmacol Physiol.
45:969–977. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Sen Z, Zhan XK, Jing J, Yi Z and Wanqi Z:
Chemosensitizing activities of cyclotides from Clitoria ternatea in
paclitaxel-resistant lung cancer cells. Oncol Lett. 5:641–644.
2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lortet-Tieulent J, Soerjomataram I, Ferlay
J, Rutherford M, Weiderpass E and Bray F: International trends in
lung cancer incidence by histological subtype: Adenocarcinoma
stabilizing in men but still increasing in women. Lung Cancer.
84:13–22. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Vansteenkiste J, Crinò L, Dooms C,
Douillard JY, Faivre-Finn C, Lim E, Rocco G, Senan S, Van Schil P,
Veronesi G, et al: 2nd ESMO Consensus Conference on Lung Cancer:
Early-stage non-small-cell lung cancer consensus on diagnosis,
treatment and follow-up. Ann Oncol. 25:1462–1474. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Parr C, Gan CH, Watkins G and Jiang WG:
Reduced vascular endothelial growth inhibitor (VEGI) expression is
associated with poor prognosis in breast cancer patients.
Angiogenesis. 9:73–81. 2006.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhang N, Sanders AJ, Ye L and Jiang WG:
Vascular endothelial growth inhibitor in human cancer (Review). Int
J Mol Med. 24:3–8. 2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhang N, Sanders AJ, Ye L, Kynaston HG and
Jiang WG: Vascular endothelial growth inhibitor, expression in
human prostate cancer tissue and the impact on adhesion and
migration of prostate cancer cells in vitro. Int J Oncol.
35:1473–1480. 2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhang N, Sanders AJ, Ye L, Kynaston HG and
Jiang WG: Expression of vascular endothelial growth inhibitor
(VEGI) in human urothelial cancer of the bladder and its effects on
the adhesion and migration of bladder cancer cells in vitro.
Anticancer Res. 30:87–95. 2010.PubMed/NCBI
|
|
13
|
Wu L, Li X, Ye L, Shayiremu D, Deng X,
Zhang X, Jiang W, Yang Y, Gong K and Zhang N: Vascular endothelial
growth inhibitor 174 is a negative regulator of aggressiveness and
microvascular density in human clear cell renal cell carcinoma.
Anticancer Res. 34:715–22. 2014.PubMed/NCBI
|
|
14
|
Zhao Q, Liu T, Hong B, Wang F, Zhou C, Du
X, Chen S, Deng X, Duoerkun S, Li Q, et al: Vascular endothelial
growth inhibitor, a cytokine of the tumor necrosis factor family,
is associated with epithelial-mesenchymal transition in renal cell
carcinoma. Appl Immunohistochem Mol Morphol. 26:727–733.
2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hou W, Medynski D, Wu S, Lin X and Li LY:
A new isoform of TNFSF15, specifically eliminates tumor vascular
endothelial cells and suppresses tumor growth. Clin Cancer Res.
11:5595–5602. 2005.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Liang PH, Tian F, Lu Y, Duan B, Stolz DB
and Li LY: Vascular endothelial growth inhibitor (VEGI; TNFSF15)
inhibits bone marrow-derived endothelial progenitor cell
incorporation into Lewis lung carcinoma tumors. Angiogenesis.
14:61–68. 2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Chen Y, Mathy NW and Lu H: The role of
VEGF in the diagnosis and treatment of malignant pleural effusion
in patients with non-small cell lung cancer (Review). Mol Med Rep.
17:8019–8030. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Karoor V, Le M, Merrick D, Fagan KA,
Dempsey EC and Miller YE: Alveolar hypoxia promotes murine lung
tumor growth through a VEGFR-2/EGFR-dependent mechanism. Cancer
Prev Res (Phila). 5:1061–1071. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yu X, Li W, Deng Q, You S, Liu H, Peng S,
Liu X, Lu J, Luo X, Yang L, et al: Neoalbaconol Inhibits
angiogenesis and Tumor Growth by suppressing EGFR-mediated VEGF
production. Mol Carcinog. 56:1414–1426. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
20
|
Zhang K, Cai HX, Gao S, Yang GL, Deng HT,
Xu GC, Han J, Zhang QZ and Li LY: TNFSF15 suppresses VEGF
production in endothelial cells by stimulating miR-29b expression
via activation of JNK-GATA3 signals. Oncotarget. 7:69436–69449.
2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Gao Y, Ge Z, Zhang Z, Bai Z, Ma X and Wang
Y: Vascular endothelial growth inhibitor affects the invasion,
apoptosis and vascularisation in breast cancer cell line
MDA-MB-231. Chin Med J (Engl). 127:1947–1953. 2014.PubMed/NCBI
|
|
22
|
Jia W, Sander AJ, Jia G, Ni M, Liu X, Lu R
and Jiang WG: Vascular endothelial growth inhibitor (VEGI) is an
independent indicator for invasion in human pituitary adenomas.
Anticancer Res. 33:3815–3822. 2013.PubMed/NCBI
|
|
23
|
Duan L, Yang G, Zhang R, Feng L and Xu C:
Advancement in the research on vascular endothelial growth
inhibitor (VEGI). Target Oncol. 7:87–90. 2012.PubMed/NCBI View Article : Google Scholar
|
